January 2011
Worldwide Biotech;Jan2011, Vol. 23 Issue 1, p6
Trade Publication
This article reports on the publication of the pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) conducted by Auxilium Pharmaceuticals Inc. in 2010. The company announced the publication of the trial in the December 2010 online edition of "The Journal of Hand Surgery (JHS)." David Gilpin, study investigator and surgeon at the Brisbane Hand and Upper Limb Clinic, noted the drug's efficacy and safety.


Related Articles

  • Clinic Roundup.  // BioWorld Today;3/26/2013, Vol. 24 Issue 59, p4 

    This section offers news briefs concerning drug clinical trials. Auxilium Pharmaceuticals Inc. reported positive data from the Phase IIa open-label study of Xiaflex therapeutic safety in adhesive capsulitis. OncoSec Medical Inc. posted positive response results from its Phase II clinical trial...

  • Clinic Roundup.  // BioWorld Today;3/10/2011, Vol. 22 Issue 47, p2 

    This section offers news briefs related to biotechnology firms as of March 2011, including the submission of an investigational new drug application to the U.S. Food and Drug Administration (FDA) by Adamis Pharmaceuticals Corp., the status of Auxilium Pharmaceutical Incorporated's study of...

  • CLINIC ROUNDUP.  // BioWorld Today;5/23/2007, Vol. 18 Issue 100, p3 

    The article offers news briefs on clinical trials. Improvements in symptoms of decreased libido and erectile dysfunction in hypogonadal men were reported by Auxilium Pharmaceuticals Inc. in a retrospective data reported at an American Urological Association meeting. A phase I-data showing...

  • Biologic breakdown. Krader, Cheryl Guttman // Dermatology Times;Apr2010 Advances on Psoriasis Suppl, Vol. 31, p8 

    The article reports on the results of the Active Comparative (CNTO1275/Enbrel) Psoriasis Trial (ACCEPT), which randomized 903 patients into three groups to receive subcutaneous ustekinumab given in two doses. According to doctor Alan Menter, the superiority of ustekinumab shows the promise of...

  • Should We Abandon Ezetimibe? LIBEROPOULOS, EVANGELOS N.; RIZOS, CHRISTOS V.; ELISAF, MOSES S. // Current Medical Literature: Cardiology;2008, Vol. 27 Issue 3, p77 

    The article discusses a study on the clinical benefits of ezetimibe in decreasing lower density lipoprotein cholesterol alone or combined with statin. A randomized trial was used to evaluate the effects of ezetimibe. The results of the study show that its use may be effective and safe but finds...

  • Early phase-3 results suggest clevidipine safe, effective for some patients. Raible, Eric; Messerli, Franz. H. // Cardiology Today;Apr2008, Vol. 11 Issue 4, p27 

    The article reports the results of a clinical trial for clevidipine, an antihypertensive drug. Findings showed that the drug was effective in treating acute severe hypertension. The drug actively lowered BP in 19 patients with acute hypertension and 24 patients with renal dysfunction. More than...

  • Topical Methyl Aminolevulinate: A Viewpoint by Lesley E. Rhodes. Rhodes, Lesley E. // American Journal of Clinical Dermatology;2004, Vol. 5 Issue 2, p138 

    Offers information on methyl aminolevulinate, a topical prodrug used in the treatment of cutaneous lesions. Indications for and administration of the prodrug; Findings of clinical trials on the application of the prodrug; Advantages of methyl aminolevulinate photodynamic therapy.

  • New psoriasis pill effective, safe.  // Cortlandt Forum;Jun2008, Vol. 21 Issue 6, p10 

    The article reports that a new type of calcineurin inhibitor showing strong promise in a clinical trial could prove to be one of the safest and most effective therapies for plaque psoriasis. In a study of people aged 18 to 65 years with plaque psoriasis, oral ISA247 reduced the psoriatic area...

  • Çoklu Sonlanım Noktalarına Sahip Klinik Denemelerde Denetleyici Test Stratejileri. TAŞDELEN, Bahar // Turkiye Klinikleri Journal of Biostatistics;2013, Vol. 5 Issue 2, p69 

    In this review, the theory and purpose of gatekeeping test strategies for the validity of test results in the clinical trials with multiple endpoints are discussed. In the clinical trials with multiple endpoints, control of Type I error is the main problem in statistical analysis of experiment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics